SOUTH SAN FRANCISCO, Calif., April 23, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the appointment of David Wheadon, M.D., to its Board of Directors. Dr. Wheadon is a health policy leader and physician with more than three decades of global experience in the pharmaceutical industry coordinating the interests of public companies, trade groups and regulators.

See the article here:
Vaxart Appoints David Wheadon, M.D., to its Board of Directors

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh